Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00274781 · OUTCOME

Overall Survival

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes · Source last updated 2015-07-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
From date of enrollment to a minimum of three years for survival

What was measured

Patient's Overall Survival from date of enrollment to a minimum of three years for survival.

Groups in this outcome

ATO (0.25mg/kg) and GO (3mg/m2)

ATO dosing was based on the phase 2 European Union regimen at a dose of 0.25 mg/kg administered intravenously on Days 1 through 5 during Week 1 and then twice weekly during Weeks 2 to 12, and GO at a dose of 3mg/m2 on Day 8 for 1 or 2 cycles of 12 weeks each.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ATO (0.25mg/kg) and GO (3mg/m2)30

Reported measurements

Overall Survival
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
ATO (0.25mg/kg) and GO (3mg/m2)9.7Not reported.7538Not reported
Responders Overall Survival
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
ATO (0.25mg/kg) and GO (3mg/m2)28.6Not reported3.538Not reported
Nonresponders Overall Survival
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
ATO (0.25mg/kg) and GO (3mg/m2)7.6Not reported0.7538Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        .75
        upper Limit
        38
        value
        9.7
    title
    Overall Survival
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.5
        upper Limit
        38
        value
        28.6
    title
    Responders Overall Survival
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.75
        upper Limit
        38
        value
        7.6
    title
    Nonresponders Overall Survival
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Patient's Overall Survival from date of enrollment to a minimum of three years for survival.
dispersion Type
Full Range
groups
  1. description
    ATO dosing was based on the phase 2 European Union regimen at a dose of 0.25 mg/kg administered intravenously on Days 1 through 5 during Week 1 and then twice weekly during Weeks 2 to 12, and GO at a dose of 3mg/m2 on Day 8 for 1 or 2 cycles of 12 weeks each.
    id
    OG000
    title
    ATO (0.25mg/kg) and GO (3mg/m2)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From date of enrollment to a minimum of three years for survival
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice